ERBB2 and breast cancer: At present, for advanced hormone receptor-positive (HR+) human epidermal growth factor receptor type 2-negative (HER2-) BC patients, endocrine therapy (ET) is often recommended by the guidelines when they have no resistance to visceral disease or ET [12].